Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D. Strober B, et al. Among authors: alexis af. J Eur Acad Dermatol Venereol. 2024 Aug;38(8):1543-1554. doi: 10.1111/jdv.19925. Epub 2024 Mar 7. J Eur Acad Dermatol Venereol. 2024. PMID: 38451052 Clinical Trial.
A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council.
Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, Cork MJ, Danby SG, Eichenfield LF, Eyerich K, Gooderham M, Guttman-Yassky E, Hijnen DJ, Irvine AD, Katoh N, Murrell DF, Leshem YA, Levin AA, Vittrup I, Olydam JI, Orfali RL, Paller AS, Renert-Yuval Y, Rosmarin D, Silverberg JI, Thyssen JP, Ständer S, Stefanovic N, Todd G, Yu J, Simpson EL. Haag C, et al. Br J Dermatol. 2024 Dec 23;192(1):135-143. doi: 10.1093/bjd/ljae342. Br J Dermatol. 2024. PMID: 39250758 Free article.
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.
Armstrong AW, Alexis AF, Blauvelt A, Silverberg JI, Feeney C, Levenberg M, Chan G, Zhang F, Fostvedt L. Armstrong AW, et al. Among authors: alexis af. Dermatol Ther (Heidelb). 2024 Jul;14(7):1849-1861. doi: 10.1007/s13555-024-01183-3. Epub 2024 Jun 19. Dermatol Ther (Heidelb). 2024. PMID: 38896380 Free PMC article.
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.
Alexis AF, Gooderham M, Kwatra SG, Amin A, Taylor S, Espaillat R, Rettig T, Wu T, Shi L, Kaldas MI, Dilley DM, Sinvhal R, Nduaka C, Lockshin B. Alexis AF, et al. Dermatol Ther (Heidelb). 2024 Oct;14(10):2877-2887. doi: 10.1007/s13555-024-01268-z. Epub 2024 Oct 2. Dermatol Ther (Heidelb). 2024. PMID: 39358667 Free PMC article.
Reducing disparities in the care of atopic dermatitis.
Nwaneri U, Heath C, Alexis A, Friedman A, Silverberg JI. Nwaneri U, et al. Arch Dermatol Res. 2024 Oct 15;316(10):688. doi: 10.1007/s00403-024-03272-x. Arch Dermatol Res. 2024. PMID: 39404903 Review.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
113 results